07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , May 23, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/20 clsArbutus Biopharma Corp. (NASDAQ:ABUS)Chardan CapitalMadhu KumarNewSell-6%$4.08 Kumar initiated coverage with a $3.25 target, saying competition to Arbutus' lead asset, ARB-1467, raises hurdles ahead of 2H16 catalysts. He...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015, a biosimilar of...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Epirus, Polpharma deal

Epirus partnered with Polpharma to develop and commercialize biosimilars BOW015, BOW050 and BOW070. BOW015 is a biosimilar of Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and ...